The PD-1 inhibitor nivolumab, in combination with azacytidine, may represent an effective treatment option for some patients with relapsed acute myeloid leukemia (AML).
Patients with acute myeloid leukemia (AML) and TP53 mutations may benefit from certain types of low-intensity chemotherapy.
In a phase 1 study, the mIDH2 inhibitor enasidenib showed promise as a potential emerging therapy for patients with relapsed or refractory acute myeloid leukemia (AML).
Synthetic control arms may represent an efficient, cost-effective way to evaluate early end points in clinical trials.
Building on the results of a prior study, the combination of sorafenib and 5-azacytidine demonstrates promise in the treatment of older patients with FLT3-ITD–positive acute myeloid leukemia.
In this analysis, minimal residual disease (MRD)-negative status in patients with acute myeloid leukemia (AML) translated into lower risk of relapse but not improved relapse-free survival or overall survival.
A recent analysis suggests that molecular response to gilteritinib may correlate with clinical response and improved overall survival.
Learn more about our family of publications.
View Our Publications